Companies › Ocugen
4 active drug programs in 6 registered trials: 3 Phase 1, 2 Phase 3, 1 Phase 2; Ophthalmology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OCU400 Gene therapy vector for retinitis pigmentosa and Leber congenital amaurosis | RHO, NR2E3, CEP290 | Phase 3 | Retinitis Pigmentosa | Feb 2027 |
| OCU410 Gene therapy for geographic atrophy | – | Phase 3 | Dry Age-related Macular Degeneration; Geographic Atrophy | Jul 2028 |
| OCU410ST Gene therapy for retinal degeneration | – | Phase 2 | Stargardt Disease | – |
| OCU200 | – | Phase 1 | Center Involved Diabetic Macular Edema | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05802329 | OCU200 | Phase 1 | Center Involved Diabetic Macular Edema | Ophthalmology | Jul 2026 |
| NCT05956626 | OCU410ST | Phase 2 | Stargardt Disease | Ophthalmology | Sep 2026 |
| NCT06388200 | OCU400 | Phase 3 | Retinitis Pigmentosa | Ophthalmology | Feb 2027 |
| NCT05203939 | OCU400 | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Mar 2027 |
| NCT07770828 | OCU410 | Phase 3 | Dry Age-related Macular Degeneration | Ophthalmology | Jul 2028 |
| NCT06018558 | OCU410 | Phase 1 | Geographic Atrophy | Ophthalmology | Feb 2030 |
Cash and short-term investments of $84m on 2026-09-30; operating cash outflow about $67m a year; runway about 15 months at that burn, to Jan 2028; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
ProQR Therapeutics Laboratoires Thea Opus Genetics Kiora Pharmaceuticals Huons
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.